BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
07 sept. 2023 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
20 juin 2023 08h00 HE
|
BeyondSpring, Inc.
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the...
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
07 juin 2023 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
18 mai 2023 08h30 HE
|
BeyondSpring, Inc.
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
18 avr. 2023 16h30 HE
|
BeyondSpring, Inc.
- SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration - BeyondSpring Completed Enrollment of Three Investigator-Initiated Trials (IIT) with Plinabulin...
BeyondSpring Files 2022 Annual Report on Form 20-F
18 avr. 2023 16h30 HE
|
BeyondSpring, Inc.
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global biopharmaceutical company focused on using its novel...
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
01 mars 2023 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative...
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
09 janv. 2023 16h30 HE
|
BeyondSpring, Inc.
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative...
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
13 déc. 2022 08h00 HE
|
BeyondSpring, Inc.
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving...
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
23 nov. 2022 16h30 HE
|
BeyondSpring, Inc.
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative...